Skip to contentpdufa.bio

TP-05 Calliope

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

TP-05 Calliope is a Tarsus Pharmaceuticals, Inc. program in lyme disease prevention. Its next catalyst is a Readout in Q2 2027.

TARS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Lyme disease prevention. Sponsor: Tarsus Pharmaceuticals, Inc. (TARS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027TARS

Specialist biotech funds holding TARS, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RTW Investments3,484,066$273.9 millionfiled November 16, 2026
Cormorant Asset Management50,000$3.9 millionfiled November 16, 2026
OrbiMed Advisors34,600$2.7 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is TP-05 Calliope's next FDA decision or readout?

The next tracked catalyst for TP-05 Calliope is a Readout in Q2 2027.

What happened at TP-05 Calliope's most recent FDA decision?

No FDA decision for TP-05 Calliope is in our archive yet.

What is TP-05 Calliope used for?

In our records TP-05 Calliope is under review or in development for Lyme disease prevention.

Who makes TP-05 Calliope?

Tarsus Pharmaceuticals, Inc. (TARS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.